MIAMI--(BUSINESS WIRE)-- Non-Invasive Monitoring Systems, Inc. [NIMS](OTCBB:NIMU) announced today that the Mexican Ministry of Health has approved the registration of NIMS’ Exer-Rest® acceleration therapeutic platform as a Class I medical device, and that NIMS appointed Medica Avante as its exclusive Mexican Exer-Rest distributor.
The distribution agreement requires Medica Avante to purchase a minimum number of Exer-Rest units, which are expected to be sold to Mexican hospitals, physical therapy facilities, pain centers, senior living communities and individuals. Medica Avante has already placed an initial order.
“Over the past several months, Medica Avante had healthcare professionals evaluate our technology of Whole Body Periodic Acceleration (WBPA) therapy for chronic neurological disorders and they were quite satisfied with patient outcomes,” stated Dr. Marvin A. Sackner, CEO of NIMS. “We are pleased to have Medica Avante market the Exer-Rest in Mexico.”
“We are very excited to represent NIMS’ latest technology,” said Roberto Prego-Novo, President of Medica Avante. “With its excellent scientific support and the need for a drug-free device to aid cardiovascular health and reduce pain in both active and sedentary adults, the Exer-Rest has the potential to be a successful product.”
WBPA therapy produced by NIMS’ Exer-Rest has been demonstrated to naturally increase the body’s release of beneficial mediators like Nitric Oxide. The Exer-Rest is an FDA listed medical device intended as an aid to temporarily increase local circulation, to provide temporary relief of minor aches and pains, to reduce morning stiffness and to provide local muscle relaxation.
Exer-Rest is cleared to market in the USA, Canada, UK, EU and Mexico.
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA). Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks and uncertainties associated with, among other things, the uncertainty of the success, if any, of the Distribution Agreement between NIMS and Medica Avante, market acceptance of the Exer-Rest in Mexico, future financial results, government approval processes, technological changes, and other uncertainties. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
NIMS, Miami, FL
Steven Mrha, 305-575-4200
KEYWORDS: United States Mexico North America Central America Florida
INDUSTRY KEYWORDS: Health Hospitals Medical Devices Other Health FDA General Health